J&J says drug combo contains lung cancer from spreading for longer duration

The therapy met the main goals of the study that tested a combination of antibody treatment Rybrevant and experimental drug lazertinib against chemotherapy in patients with a more common mutation in EGFR protein that causes rapid cell growth. J&J's therapy was tested in patients in whom the disease progressed even after they were treated with AstraZeneca's Tagrisso. Rybrevant received approval in 2021 for only 2-3% of non small-cell lung cancer (NSCLC) patients – a small subset that had a specific type of mutation in EGFR protein.